Global Oral Ursodeoxycholic Acid Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Oral Ursodeoxycholic Acid Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Ursodeoxycholic acid, whose chemical name is 3a,7β-dihydroxy-5β-cholestane-24-acid, is an organic compound with an odorless, bitter taste. It is used in medicine to increase the secretion of bile acid, change the composition of bile, reduce cholesterol and cholesterol lipid in bile, and help the cholesterol in gallstones to gradually dissolve.
Oral Ursodeoxycholic Acid report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Oral Ursodeoxycholic Acid market is projected to reach US$ 3436.9 million in 2029, increasing from US$ 1628 million in 2022, with the CAGR of 11.3% during the period of 2024 to 2029. Demand from Gallstones and Liver Disease are the major drivers for the industry.
The Ursodeoxycholic Acid (UDCA) drug market is driven by the increasing prevalence of liver and gallbladder disorders and the growing adoption of UDCA as an effective treatment option. UDCA is a naturally occurring bile acid that helps dissolve cholesterol-rich gallstones and aids in the treatment of certain liver diseases, such as primary biliary cholangitis (PBC) and nonalcoholic fatty liver disease (NAFLD). The rise in liver-related conditions and the need for improved therapeutic options contribute to market growth as UDCA offers a well-tolerated and disease-modifying treatment for these disorders. Moreover, advancements in drug formulations and the development of combination therapies have enhanced the efficacy of UDCA treatment. However, the market also faces challenges, including the cost of UDCA drugs and the need for further research to optimize dosing and treatment protocols. Additionally, addressing regulatory requirements and ensuring accessibility to patients can pose obstacles for broader adoption. To succeed, companies must focus on research and development to offer innovative and affordable UDCA drugs, collaborate with hepatologists to optimize treatment approaches, and address the challenges to meet the increasing demand for effective and well-tolerated therapeutic options for liver and gallbladder disorders.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Oral Ursodeoxycholic Acid market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Dr. Falk Pharma
Daewoong Pharmaceutical
Teva
Epic Pharma
Mitsubishi Tanabe Pharma
Lannett
Mylan
Bruschettini
Impax
Shanghai Pharma
Grindeks
Segment by Type
Tablet
Capsule
Gallstones
Liver Disease
Stomach Trouble
Other
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Oral Ursodeoxycholic Acid market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Oral Ursodeoxycholic Acid, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Oral Ursodeoxycholic Acid industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Oral Ursodeoxycholic Acid in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Oral Ursodeoxycholic Acid introduction, etc. Oral Ursodeoxycholic Acid Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Oral Ursodeoxycholic Acid market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Oral Ursodeoxycholic Acid report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Oral Ursodeoxycholic Acid market is projected to reach US$ 3436.9 million in 2029, increasing from US$ 1628 million in 2022, with the CAGR of 11.3% during the period of 2024 to 2029. Demand from Gallstones and Liver Disease are the major drivers for the industry.
The Ursodeoxycholic Acid (UDCA) drug market is driven by the increasing prevalence of liver and gallbladder disorders and the growing adoption of UDCA as an effective treatment option. UDCA is a naturally occurring bile acid that helps dissolve cholesterol-rich gallstones and aids in the treatment of certain liver diseases, such as primary biliary cholangitis (PBC) and nonalcoholic fatty liver disease (NAFLD). The rise in liver-related conditions and the need for improved therapeutic options contribute to market growth as UDCA offers a well-tolerated and disease-modifying treatment for these disorders. Moreover, advancements in drug formulations and the development of combination therapies have enhanced the efficacy of UDCA treatment. However, the market also faces challenges, including the cost of UDCA drugs and the need for further research to optimize dosing and treatment protocols. Additionally, addressing regulatory requirements and ensuring accessibility to patients can pose obstacles for broader adoption. To succeed, companies must focus on research and development to offer innovative and affordable UDCA drugs, collaborate with hepatologists to optimize treatment approaches, and address the challenges to meet the increasing demand for effective and well-tolerated therapeutic options for liver and gallbladder disorders.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Oral Ursodeoxycholic Acid market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Dr. Falk Pharma
Daewoong Pharmaceutical
Teva
Epic Pharma
Mitsubishi Tanabe Pharma
Lannett
Mylan
Bruschettini
Impax
Shanghai Pharma
Grindeks
Segment by Type
Tablet
Capsule
Segment by Application
Gallstones
Liver Disease
Stomach Trouble
Other
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Oral Ursodeoxycholic Acid market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Oral Ursodeoxycholic Acid, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Oral Ursodeoxycholic Acid industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Oral Ursodeoxycholic Acid in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Oral Ursodeoxycholic Acid introduction, etc. Oral Ursodeoxycholic Acid Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Oral Ursodeoxycholic Acid market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices